罗氟司特治疗支气管哮喘的效果数据

Bronchial asthma (BA) is a chronic inflammatory disease characterized by airway reconstruction. Clinical manifestations include wheezing, dyspnea, and repeated coughing. If timely and effective treatment is not available, it can easily lead to acute exacerbation and even death. Data show that although ICS has good efficacy in the treatment of BA, it often cannot completely control the acute exacerbation of BA, and some patients are not sensitive to ICS treatment. It is a new type of PDE4 inhibitor that has the effects of anti-inflammation, inhibiting airway remodeling and regulating the body's immunity. Its application in the clinical treatment of BA has certain efficacy. Let's take a look at the efficacy data of roflumilast in the treatment of bronchial asthma.

128 patients with acute exacerbation of BA were selected and divided into a roflumilast group and a control group with 64 cases each according to the random number table method. The control group was given conventional treatment + budesonide suspension, and the roflumilast group was given conventional treatment + budesonide suspension + roflumilast.

Results After treatment, the forced vital capacity (FVC), peak expiratory flow rate (PEF), forced expiratory volume in first second (FEV1) and serum INF-γ, CD4+, CD4+/CD8+ levels in the roflumilast group were higher than those in the control group (P<0.05). The ratio of airway wall area to total airway cross-sectional area (WA%), T/D and serum TNF-α, IL-17 and CD8+ levels were lower than those in the control group (P<0.05). The total effective rate of the roflumilast group was better than that of the control group (P<0.05). There were no serious adverse reactions in either group.

It is concluded that roflumilast can correct the body's inflammatory immune imbalance, inhibit airway remodeling, improve lung function and serological indicators, improve efficacy, and is safe and reliable in treating acute exacerbation of BA.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.